Wedbush Equities Analysts Raise Earnings Estimates for Janux Therapeutics, Inc. (NASDAQ:JANX)

Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) – Research analysts at Wedbush upped their Q1 2024 earnings per share (EPS) estimates for shares of Janux Therapeutics in a note issued to investors on Tuesday, February 27th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings per share of ($0.40) for the quarter, […]

Related Keywords

Immunomodulator Tracir ,William Blair ,Nasdaq ,Blackrock Inc ,Metlife Investment Management ,York Mellon Corp ,Jpmorgan Chase Co ,Janux Therapeutics Company Profile ,Janux Therapeutics Inc ,Janux Therapeutics ,Free Report ,Janux Therapeutic ,New York Mellon Corp ,Life Investment Management ,Get Free Report ,Tumor Activatedt Cell Engager ,Tumor Activated Immunomodulator ,Janux Therapeutics Daily ,